Shots:

• The CHMP opinion was based on the P-II/III (EPIC-HR) trial to evaluate Paxlovid vs PBO in non-hospitalized adults aged ≥18yrs. with COVID-19 who are at high risk of progressing to sev. illness
• The results showed a reduction in risk of hospitalization or death (89% vs 88%) within 3 & 5 days of symptom onset & no deaths were observed, TEAEs (23% vs 24%). The results have been submitted to a peer-reviewed publication
• Paxlovid is currently approved or authorized for emergency use in 10+ countries globally. Additionally, P-II/II clinical trials are currently ongoing in adults at standard risk of progressing to sev. illness who have been exposed to the virus through household contacts

Ref: Businesswire | Image: Pfizer